TickerFacts.

Compare

Repligen Corp vs ADMA Biologics, Inc. vs Tarsus Pharmaceuticals, Inc. vs Halozyme Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearRepligen Corp
RGEN		ADMA Biologics, Inc.
ADMA		Tarsus Pharmaceuticals, Inc.
TARS		Halozyme Therapeutics, Inc.
HALO
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$738.26M$510.17M$451.36M$1.40B
Revenue growth (YoY)+16.4%+19.6%+146.7%+37.6%
Gross margin52.3% (computed)57.4%n/a83.6% (computed)
Operating margin7.5%37.5%-15.7%33.6%
Net margin6.6%28.8%-14.7%22.7%
Net income$48.89M$146.93M-$66.42M$316.89M
EPS (Diluted)$0.86$0.60-$1.59$2.56
Operating cash flow$117.42M$50.40M-$12.45M$651.56M
Free cash flow$93.90M$27.82M-$22.31M$644.59M
Cash & equivalents$566.02M$87.63M$183.64M$133.82M
Total assets$2.95B$624.24M$562.16M$2.53B
Total liabilities$843.57M$146.92M$218.73M$2.48B
Shareholders' equity$2.11B$477.32M$343.43M$48.81M
Return on year-end equity2.3%30.8%-19.3%649.2%
Shares outstanding56.33M237.87M42.55M117.78M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearRepligen CorpADMA Biologics, Inc.Tarsus Pharmaceuticals, Inc.Halozyme Therapeutics, Inc.
Latest$738.26M
Ended 2025-12-31		$510.17M
Ended 2025-12-31		$451.36M
Ended 2025-12-31		$1.40B
Ended 2025-12-31
1 year earlier$634.44M
Ended 2024-12-31		$426.45M
Ended 2024-12-31		$182.95M
Ended 2024-12-31		$1.02B
Ended 2024-12-31
2 years earlier$632.36M
Ended 2023-12-31		$258.21M
Ended 2023-12-31		$17.45M
Ended 2023-12-31		$829.25M
Ended 2023-12-31
3 years earlier$801.54M
Ended 2022-12-31		$154.08M
Ended 2022-12-31		$25.82M
Ended 2022-12-31		$660.12M
Ended 2022-12-31
4 years earlier$670.53M
Ended 2021-12-31		$80.94M
Ended 2021-12-31		$57.03M
Ended 2021-12-31		$443.31M
Ended 2021-12-31